Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

NCT04647526 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

455

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG: [Lu-177]-PNT2002
DRUG: Abiraterone
DRUG: Enzalutamide

Sponsor

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company